Cathie Wood Adds 30K More Tempus AI Stock Following Deep 6 AI Buyout News
Light Up your Portfolio with Spark:
Easily identify stocks' risks and opportunities.
Discover stocks' market position with detailed competitor analyses.
Wood Is Buying the Dip in Tempus AI
Ark's recent purchasing activity displays the ace hedge fund manager's solid conviction in the AI (artificial intelligence) powered precision medicine company. Wood has been on a buying spree of Tempus AI stock, leveraging the recent dip in the stock price. On March 11, Wood purchased 94,251 shares of Tempus AI, worth $4.29 million. In the past five trading sessions, TEM stock has lost 7.1%. After yesterday's purchase, Tempus AI ranks eight on the ARKK fund's top ten holdings list, representing 4.37% of the total portfolio.
Hedge Funds Are Showing Confidence in TEM Stock
Interestingly, hedge funds are showing a growing confidence in the future potential of the AI-powered biotechnology company. According to TipRanks Hedge Fund Trading Activity Tool, Tempus AI stock has a Very Positive Confidence Signal as several hedge funds increased their holdings of TEM stock by 3.2 million shares in the last quarter.
Notably, Ark Invest ETFs were one of the largest accumulators of Tempus AI stock during the last quarter, with a reported value of $186.34 million.
Is Tempus AI Stock a Good Buy?
Analysts remain divided on Tempus AI's stock trajectory. On TipRanks, TEM stock has a Moderate Buy consensus rating based on five Buys versus five Hold ratings. Also, the average Tempus AI price target of $63.67 implies 39.9% upside potential from current levels. Year-to-date, TEM stock has gained 34.8%.
See more TEM analyst ratings
Disclosure
Questions or Comments about the article? Write to editor@tipranks.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14-07-2025
- Globe and Mail
BMO Announces Final Valuations and Declares Final Distributions on Units of ETF Series of Terminated BMO Mutual Funds
TORONTO, July 14, 2025 /CNW/ - BMO Investments Inc. ("BMOII") today announced the final net asset values for the ETF Series of each of BMO ARK Genomic Revolution Fund (Cboe Canada: ARKG), BMO ARK Innovation Fund (Cboe Canada: ARKK) and BMO ARK Next Generation Internet Fund (Cboe Canada: ARKW) (each, a "Fund" and collectively, the "Funds").
The Market Online
14-07-2025
- The Market Online
Capitalizing on the central bank gold rush: Barrick Mining's production, Dryden Gold's exploration, and Deutsche Bank's interest rate concerns
Gold is once again shining as a strategic anchor in turbulent times. Global central banks, especially those in emerging markets, are massively expanding their reserves, driven by geopolitical risks, currency diversification, and inflation concerns. At the same time, central banks like the ECB are lowering interest rates, which on the one hand offers banks cheaper refinancing, but on the other hand squeezes margins and increases credit risks. This dynamic mix of a gold rush, monetary policy shift, and inflationary pressure is forcing financial players to rethink their strategies. In this context, we take a look at two gold companies, Barrick Mining and Dryden Gold (TSXV:DRY), and analyze the current outlook for Deutsche Bank. This article is disseminated in partnership with Apaton Finance GmbH. It is intended to inform investors and should not be taken as a recommendation or financial advice. Barrick Mining – Strong tailwind despite Mali cloud The conflict between Barrick Mining and the Malian government remains a significant burden. Since June, the important Loulo-Gounkoto mine, which was responsible for approximately 10% of production, has been under forced administration. Most recently, a military helicopter transported gold worth approximately USD 100 million, reportedly to finance operations that Malian authorities resumed against Barrick's wishes. CEO Mark Bristow considers this move illegitimate and warns of long-term damage. Production has been at a standstill since January while international arbitration proceedings are ongoing. This uncertainty continues to weigh on the Company. Despite the challenges in Mali, Barrick is showing strength elsewhere. In the Congo, the Kibali mine is advancing exploration in the promising ARK-KCD corridor, which could extend its life. It is a showcase project for local value creation and ecology, with 85% of its energy coming from renewable sources. In Tanzania, the 'Twiga' partnership with the government is celebrating its fifth year. It has already injected nearly USD 5 billion into the local economy. And in Zambia, the billion-dollar expansion of the Lumwana copper mine is progressing on schedule, which is expected to double its production. Things are running smoothly here. Barrick continues to impress with solid fundamentals. The Company operates efficiently with high margins and a robust balance sheet with low net debt. Management is strategically streamlining the portfolio, for example, by selling Donlin, and focusing on first-class projects such as the huge Reko Diq copper-gold project. Barrick appears attractive in terms of valuation: An expected price-to-earnings ratio (P/E) of around 11.6x and an extremely low price-to-earnings growth ratio of 0.34x indicate an undervalued company that is growing profitably, even if Mali currently remains a shadow. Despite Mali, the share price has recently risen and is currently trading at USD 21.22. Dryden Gold – More than just drill holes in the ground In Ontario's well-established gold belt, Dryden Gold (TSXV:DRY) is focusing on a large, consolidated land package of over 700 sq km around the town of Dryden, targeting high-grade gold structures. The Gold Rock Camp project stands out in particular, where both historical and current drilling has confirmed exceptional gold grades, in some cases up to 53,700 g/t, in near-surface, cluster-like zones. But what truly sets Dryden apart from other explorers is its location: existing roads, power, and an experienced local workforce help keep drilling costs well below the industry average at around CAD 250 per meter and allow for year-round exploration. A data-driven drilling program of 15,000 meters is currently underway and is already delivering spectacular results. In May, 80 meters from the main Jubilee zone, gold grades of 301.67 g/t over 3.9 meters were discovered in the newly discovered Hanging Wall Zone in drill hole KW-25-003. Surface samples confirm an extension of the mineralized trend by 2 km. On June 19, high-grade discoveries of up to 28.6 g/t and 25.8 g/t were also reported in the Laurentian and Pearl target areas. No detailed assay results are available yet for the two most recent drill holes, but the Company was able to report that visible gold was found in the drill core. At the end of the fully funded drill program, the Company expects to have a clear understanding of the overall extent of the properties. Dryden pursues an iterative exploration style. Field programs and drill results are continuously analyzed to dynamically adjust target areas, both in the known Gold Rock Camp and at new depths and regional targets such as Hyndman. This flexible, data-driven approach, combined with operational efficiency and a mining-friendly environment, forms the foundation for potential value creation. The Company is led by professionals who have proven time and again how to successfully build and sell exploration companies. Well-known industry giants such as Centerra Gold and Alamos Gold among the shareholders highlight the confidence in the project and strategy. Management and insiders themselves hold substantial shares, which is always a positive sign. The stock is currently trading at CAD 0.215. Deutsche Bank – Between interest rate pressure and new strength Falling key interest rates are weighing heavily on Deutsche Bank, particularly in its private and corporate banking business. In the current year, it has already lost around 4% of its net interest income, mainly due to narrower margins on deposits and loans. While traditional interest-earning business is suffering, other areas are proving more robust. Investment banking and asset management are benefiting from stable commission income. The bank is partially offsetting interest rate pressure through higher deposit volumes, but the normalization is clearly putting traditional sources of income under stress. Despite the headwinds in interest income, the bank recently reported its highest quarterly profit in 14 years. The key lies in its broader positioning. Strong trading results in investment banking, due to market volatility and solid asset management, offset the weaknesses. At the same time, consistent cost management is optimizing the operating base. The cost-income ratio is already below 65%. In addition, active interest rate management via hedging mitigates fluctuations. This mix of diversification and discipline supports the target return on equity of over 10%. However, structural challenges remain. Regulatory risk and sustained market confidence continue to be critical issues. Internally, the bank is working to fully implement its efficiency targets and tap into growth areas. For example, wealth management in Germany was recently reorganized to streamline management and expand market share. For investors, the question remains whether the bank can translate its operational strength into lasting credibility. The ambitions are there, and the test is underway. A share currently costs EUR 25.38. The central banks' gold rush is fueling demand, but players must overcome various challenges. Barrick Mining is battling the crippling Mali conflict despite its operational strength and attractive valuation. Dryden Gold is scoring points with cost-efficient exploration in established areas and a determined search for high-grade deposits. Deutsche Bank is struggling with falling interest rates, but is partially offsetting this through diversification and cost control. While mines and explorers are benefiting from the tailwind provided by the gold price, the financial sector must prove its earning power in the new interest rate era – gold remains a strategic anchor in times of crisis. Conflict of interest Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as 'Relevant Persons') may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a 'Transaction'). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company. In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships. For this reason, there is a concrete conflict of interest. The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies. Risk notice Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such. The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user. The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Globe and Mail
02-07-2025
- Globe and Mail
What's Fueling Tempus AI's Explosive Sales Growth?
Chicago-based Tempus AI, Inc. TEM is experiencing robust revenue growth, marked by record-setting financial performance. In the first quarter of 2025, the company reported a 75.4% year-over-year increase in total revenues, driven by 89% growth in Genomics revenues and a 43% rise in Data & Services revenues. The Genomics business benefited from 20% volume growth in oncology tests (legacy Tempus clinical testing) and higher average revenue per test, driven by increased Medicare reimbursement rates. Additionally, hereditary testing contributed $63.5 million in Genomics revenues on 23% volume growth from the February acquisition of Ambry Genetics. The Data & Services segment's growth was driven by a 58% improvement in Insights, the company's data licensing business. This business has scaled significantly by signing deals with companies like Novartis, Merck EMD, Takeda and United Therapeutics last year. TEM made several recent developments that are setting the stage for sales growth. In line with this, Tempus AI signed a $200 million data and modeling license agreement with AstraZeneca AZN and Pathos to build the world's largest foundation model. Additionally, the company's new liquid biopsy assay, xM for treatment response monitoring (TRM), is scheduled for clinical launch in the coming months. Furthermore, the company's first whole-genome sequencing (WGS) test, Xh, is slated for clinical launch by next year. Sales Growth of TEM's Competitors Exact Sciences Corporation EXAS posted a 10.9% revenue rise in the first quarter of 2025, led by strong growth in its Screening segment, driven by strong adoption of Cologuard (a non-invasive, patient-friendly, stool-based DNA screening test) and the launch of Cologuard Plus. Precision Oncology revenues grew 4% due to continued adoption of Oncotype DX (cancer diagnostic tests and services) and the launch of Oncodetect, a molecular residual disease test. Adjusted EBITDA rose 61% to $63 million, supported by volume leverage and operational efficiency. Exelixis EXEL reported strong revenue growth in the first quarter of 2025, with total revenues increasing 30.6% year over year. The performance was largely driven by the ongoing success of the Cabozantinib franchise, particularly the recent U.S. launch of CABOMETYX for the treatment of advanced neuroendocrine tumors. TEM's Price Performance and Valuation In the past year, Tempus AI shares have surged 79.1%, outperforming the industry's 39.9% growth and the S&P 500 composite's 13% improvement. TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.85X compared to the industry average of 5.91X. TEM Stock Estimate Trend Earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture. TEM stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Exact Sciences Corporation (EXAS): Free Stock Analysis Report Tempus AI, Inc. (TEM): Free Stock Analysis Report This article originally published on Zacks Investment Research (
